MONTROSE, MICHIGAN – 6 Mar, 2017 – When activated by exposure to the non-psychoactive marijuana extract Cannabidiol (CBD), the human body’s cannabinoid 1 and cannabinoid 2 receptors (CB1 & CB2) in the body’s endocannabinoid system can act as anti-tumor agents in a number of aggressive cancers.
The endocannabinoid system (ECS) is a group of endogenous (having an internal origin) cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems.
“Chemical components of Cannabis, called cannabinoids, activate specific receptors throughout the body to produce pharmaacologic effects, particularly in the central nervous system and the immune system,” according to the National Cancer Institute.
CBD has been shown to inhibit the progression of cancers located in the breast, lung, prostate, and colon in animal models, suggesting that CBD would also be effective in increasing cancer cell death in human subjects. See “The Anti-tumor Activity of Plant-Derived Non-Psychoactive Cannabinoids,” U.S. National Library of Medicine, study number NIHMS685179. Other studies have also found CBD to be effective in treating other types of cancers.
“Collectively, the non-psychoactive plant-derived cannabinoid CBD exhibits pro-apoptotic and anti-proliferative actions in different types of tumours and may also exert anti-migratory, anti-invasive, anti-metastatic and perhaps anti-angiogenic properties. On the basis of these results, evidence is emerging to suggest that CBD is a potent inhibitor of both cancer growth and spread,” summarized the cancer research report “Cannabidiol as potential anticancer drug,” U.S. National Library of Medicine, study number PMC3579246.
If one goes to the U.S. National Library of Medicine (National Institutes of Health) PubMed website https://www.ncbi.nlm.nih.gov/pubmed/ to do a search on “Cannabinoid”, there are almost 20,000 published research studies. That’s an average of more than two scientific publications per day over the last 20 years! Literally thousands of clinical studies show amazing benefits. 2042 studies determined that CBD fights cancer and tumors.
533 studies document reduction of patient chemotherapy-related nausea and vomiting by cannabinoids; 802 studies concluded that CBD helps fight neurodegenerative diseases; 221 studies find that Cannabidiol displays anti-seizure properties; 1784 studies document that CBD suppresses pain; 1168 studies concluded that CBD improves brain function; 295 studies concluded that CBD improves sleep; 1368 studies concluded that Cannabidiol protects from inflammation; and 413 studies documented anxiety relief with CBD.
THC (the separate, psychoactive marijuana extract) and CBD also been shown to be effective at lowering neuropathic pain that traditional treatment was unable to manage. In one study, cancer patients with intractable pain who had previously and unsuccessfully tried to manage their discomfort with opioids saw significant reductions in pain levels after being treated with both THC and CBD.
In addition, the National Cancer Institute recognizes cannabis as an effective treatment for providing relief of a number of symptoms associated with cancer, including pain, nausea and vomiting, anxiety, and loss of appetite.
The CBD dietary supplement is available in capsules and salves at the website www.cbdcannabidiolmeds.com. Although no physician’s prescription is required to buy CBD in any state or in forty nations outside of the USA, patients should always check first with their attending physician before starting a new dietary supplement program such as CBD.
The statements in this news release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.
Media Contact
Company Name: CBDCannabidiolmeds.com
Contact Person: Phillip Fry
Email: sales@moldinspector.com
Phone: 8106390373
Country: United States
Website: www.CBDCannabidiolmeds.com
